|
ÁÖ½Äȸ»ç ºñƼ¾Ø¾¾ |
±¹³» ¹ÙÀÌ¿À´ë±â¾÷¿¡¼ Áø´Ü°Ë»çÀÇÇÐ Àü¹®ÀÇ ¼±»ý´ÔÀ» ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.26 |
|
|
ÁÖ½Äȸ»ç ºñƼ¾Ø¾¾ |
Rare Disease ÀǾàÇ° ´ã´ç ¼±»ý´ÔÀ» ã½À´Ï´Ù(Á¦¾à ±â¾÷)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.26 |
|
|
ÁÖ½Äȸ»ç ºñƼ¾Ø¾¾ |
oncology ÀǾàÇ° medical advisorä¿ë(¿Ü±¹°è Á¦¾à ±â¾÷)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.14 |
|
|
ÁÖ½Äȸ»ç ºñƼ¾Ø¾¾ |
¹é½Å´ã´ç Àǻ缱»ý´Ô ¸ð½Ê´Ï´Ù(½ÅÀÔ, °æ·Â ¸ðµÎ Áö¿ø °¡´É)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.14 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Medical Science Liasion
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.02 |
|
|
´õÁ¸Àâ |
À¯¸íCROȸ»ç-Medical Director (MD)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
2³â¡è |
ä¿ë½Ã |
07.06 |
|
|
(ÁÖ)ÄھƼġ |
medical advisor
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Country Medical Director/À¯·´°èÇÕÀÛÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Country Medical Director/À¯·´°èÇÕÀÛÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
3³â¡è |
ä¿ë½Ã |
04.06 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
Country Head, Manager, Sr./Jr. cra ±Û·Î¹ú Pharm/cro(ÀçÅÃ
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Advisor/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Team Manager/Èñ±ÍÁúȯFranchise(±¹³» »óÀ§±ÇÀÇ Á¦
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
7³â¡è |
ä¿ë½Ã |
01.13 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Diagnostics Manager(Oncology)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
11.04 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Advisor(ÀÇ»ç)/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.03 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Medical Doctor(ÀÇÇнÇÀå) Á¦¾àÀÇ»ç ºÐÀ» ã½À´Ï´Ù.
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
°æ·Â¹«°ü |
ä¿ë½Ã |
10.21 |
|